MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)

Phase 2CompletedNCT00533208

Merck Sharp & Dohme LLC766 enrolled

Overview

To assess the efficacy of MK0524 on seasonal allergies.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

766

Conditions

Seasonal Allergies

Interventions

MK0524DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Person has had at least 2 years of seasonal allergies * Person has had a positive skin test to at least 1 of the allergens of the season * Person is a non-smoker Exclusion Criteria: * Person has been hospitalized within the last 4 weeks * Person is a female who has had a baby within the last 8 weeks or is still breast-feeding

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.